Lee Ju-Han, Cho Su Jin, Zhang Xianglan, Zheng Zhenlong, Lee Eung Seok, Kim Aeree, Kim Young-Sik, Chae Yang-Seok, Kim Insun
Department of Pathology, College of Medicine, Korea University, Guro-gu, Seoul, Korea.
J Korean Med Sci. 2006 Aug;21(4):645-51. doi: 10.3346/jkms.2006.21.4.645.
The metastasis-suppressing role of the nm23 gene in the metastatic spread of malignant tumor is still debated. We examined the nm23-H1 protein expression and gene mutation in non-Hodgkin's lymphomas to compare with the clinicopathologic parameters. The expression of nm23-H1 protein was immunohistochemically examined in 150 cases of non-Hodgkin's lymphomas; 85 diffuse large B cell lymphomas (DL-BCL), 18 marginal zone B cell lymphomas (MZL), 3 mantle cell lymphomas, 25 peripheral T cell lymphomas, not otherwise specified (TCLNOS), and 19 NK/T cell lymphomas (NK/T). Eighty-one cases (58 DLBCL, 6 MZL, 4 TCLNOS, and 13 NK/T) were studied for nm23-H1 gene mutation in exon 1 to 5. The high expression of nm23-H1 protein was associated with the high IPI score (p=0.019) and the low survival rate of the patients (p=0.0039). The gene mutation of nm23-H1 was detected in 10.3% of DLBCL and 30.7% of NK/T; but none in MZL and TCLNOS. The mutation was found in exon 1 in 5 cases, exon 2 in two cases, exon 4 in one case and both exon 1 and 2 in two cases. Our results suggest that the expression of nm23-H1 protein can be used as a poor prognostic marker in non-Hodgkin's lymphomas, and the mutational change of gene may operate in the lymphomagenesis.
nm23基因在恶性肿瘤转移扩散中的抑转移作用仍存在争议。我们检测了非霍奇金淋巴瘤中nm23-H1蛋白的表达及基因突变情况，并与临床病理参数进行比较。采用免疫组织化学方法检测了150例非霍奇金淋巴瘤中nm23-H1蛋白的表达，其中包括85例弥漫性大B细胞淋巴瘤（DL-BCL）、18例边缘区B细胞淋巴瘤（MZL）、3例套细胞淋巴瘤、25例未另行特指的外周T细胞淋巴瘤（TCLNOS）和19例NK/T细胞淋巴瘤（NK/T）。对81例患者（58例DLBCL、6例MZL、4例TCLNOS和13例NK/T）的nm23-H1基因外显子1至5进行了基因突变检测。nm23-H1蛋白的高表达与高国际预后指数（IPI）评分相关（p=0.019），且与患者低生存率相关（p=0.0039）。在10.3%的DLBCL和30.7%的NK/T中检测到nm23-H1基因突变，而在MZL和TCLNOS中未检测到。突变分别发生在外显子1的5例、外显子2的2例、外显子4的1例以及外显子1和2的2例。我们的数据表明，nm23-H1蛋白的表达可作为非霍奇金淋巴瘤预后不良的标志物，且基因的突变改变可能在淋巴瘤发生过程中起作用。
